Loading stock data…
NUWE
$1.07-0.06 (-5.31%)
Market ClosedLast close May 1
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nuwellis, Inc. in the Healthcare sector is trading at $1.07. The stock is currently near its 52-week low of $0.96, remaining 67.7% below its 200-day moving average. Technical signals show oversold RSI of 29 and bullish MACD crossover, explaining why NUWE maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 29) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.07
Potential Upside
5%
Whystock Fair Value$1.12
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.09M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-666.20%
Volume
Today's trading volume
47,909
Recent News
Nuwellis, Inc. Q4 2025 Earnings Call Summary
Moby summary of Nuwellis, Inc.'s Q4 2025 earnings call
Nuwellis (NUWE) Q4 2025 Earnings Call Transcript
In addition to myself, with us today are John L. Erb, Nuwellis, Inc.'s Chairman of the Board and CEO, and our newly appointed CFO, Carissa Schultz. At 8:00 a.m. Eastern Time today, Nuwellis, Inc. released financial results for the fourth quarter and full year 2025.
BC-Most Active Stocks
Nu Holdings Ltd. 46,657,078 18.56
Nuwellis Inc (NUWE) Q3 2025 Earnings Call Highlights: Strong Sequential Growth Amid Revenue ...
Despite a year-over-year revenue decline, Nuwellis Inc (NUWE) showcases significant growth in consumables and US console sales, while advancing strategic initiatives for long-term success.
Nuwellis Inc (NUWE) Q2 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Challenges
Nuwellis Inc (NUWE) navigates operational hurdles with strategic transitions and growth in pediatrics, despite a decline in overall revenue.